Avalyn Pharma raised $100 million to develop inhaled therapies for rare respiratory diseases, including idiopathic pulmonary fibrosis and interstitial lung diseases, improving efficacy while reducing side effects compared to oral treatments.
Avalyn Pharma raised $100 million to develop inhaled therapies for rare respiratory diseases, including idiopathic pulmonary fibrosis and interstitial lung diseases, improving efficacy while reducing side effects compared to oral treatments.
